Abstract: The anti-tumour agent paclitaxel has proved to be effective for the treatment of patients with solid tumor, and recently many results also indicate it’s clinically highly effective in patients with cervical cancer. Paclitaxel chemotherapy for cervical cancer is reviewed in three directions including monochemotherapy, and two or three drugs combination chemotherapy. The regimen of paclitaxel（T） combined with cisplatin（P） or carboplatin（C） has proved highly effective and safe, showing it is superior to monotherapy or three drugs combination therapy, especially in neoadjuvant chemotherapy. Compared with TP, TC demonstrates easiness of administration for improved renal toxicity of carboplatin. TP or TC combining with radiotherapy shows significant effect. Weekly paclitaxel has similar response rate and less adverse reaction versus the standard 3-weekly paclitaxel. Paclitaxel chemothrepy would be more popular for cervical cancer patients.

Key words: Paclitaxel, Cervical cancer, Chemotherapy